摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,6,7,8-四氢-5,5,8,8-四甲基-2-萘胺 | 92050-16-3

中文名称
5,6,7,8-四氢-5,5,8,8-四甲基-2-萘胺
中文别名
5,5,8,8-四甲基-5,6,7,8-四氢萘-2-基胺
英文名称
5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylamine
英文别名
5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine;2-amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene;5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-amine
5,6,7,8-四氢-5,5,8,8-四甲基-2-萘胺化学式
CAS
92050-16-3
化学式
C14H21N
mdl
——
分子量
203.327
InChiKey
AMDKYPNODLTUMY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    63-65℃
  • 沸点:
    310.2±31.0 °C(Predicted)
  • 密度:
    0.944

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    26
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2921450090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    应存放在室温、避光且充满惰性气体的环境中。

SDS

SDS:ac6d54437cf0ae3be7ad00c622df0222
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-amine
Synonyms: 5,5,8,8-Tetramethyl-tetrahydronaphthalen-2-amine

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5,5,8,8-Tetramethyl-6,7-dihydronaphthalen-2-amine
CAS number: 92050-16-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H21N
Molecular weight: 203.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

5,6,7,8-四氢-5,5,8,8-四甲基-2-萘胺是合成他米巴罗汀(tamibarotene)的主要原料。他米巴罗汀是一种维A酸激动剂,在日本已作为急性早幼粒细胞性白血病的治疗药物上市应用。

制备

将5,6,7,8-四氢-5,5,8,8-四甲基-2-萘甲酰胺20g投入三口瓶中,加入200ml 丙三醇及7.0g氢氧化钠,升温至150℃,搅拌2小时后冷却。将反应液倾入大量水中,放置过夜后过滤,用甲醇/水重结晶得到黄色固体14.5g,收率为87.5%。熔点(mp)为71-74℃。核磁共振氢谱(1H-NMR,300MHz,CHCl3)结果为:1.24 (6H) 1.27 (6H) 1.69 (4H) 3.5-3.9 (2H) 6.56 (1H) 6.68 (1H) 7.13 (1H)。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    视黄苯甲酸。1.芳族酰胺与类视色素活性的结构-活性关系。
    摘要:
    已显示两种类型的芳族酰胺,对苯二甲酸单苯胺和(芳基甲酰胺基)苯甲酸具有有效的类维生素A活性,可以归类为类维生素A。基于对人早幼粒细胞白血病细胞HL-60的分化诱导活性,讨论了这些酰胺的构效关系。在通式4(X = NHCO或CONH)中,引起类视色素活性的必要因素是在其间位的中等尺寸烷基(异丙基,叔丁基等)和在其对位的羧基。另一个苯环。酰胺结构的键可以颠倒,该部分显然具有将两个苯环相对于彼此定位在适当位置的作用。推测是由于所得的构象变化,在酰胺基邻位的环位置取代或酰胺基的N-甲基化导致活性降低。显然,苄基甲基和羧基的相互取向以及它们之间的距离是决定类视色素活性的必要因素。在合成的化合物中,4-[((5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)氨基甲酰基]苯甲酸(Am80)和4-[(5,6,在该测定中,7,8-四氢-5,5,8,8-四甲基-2-萘基[羧酰胺基]苯甲酸(Am580)的
    DOI:
    10.1021/jm00119a021
  • 作为产物:
    描述:
    参考文献:
    名称:
    Isolation and Proof of Structure of 1,1,4,4-Tetramethyl-6-t-butyl-1,2,3,4- tetrahydronaphthalene1
    摘要:
    DOI:
    10.1021/jo01075a008
点击查看最新优质反应信息

文献信息

  • Di(aromatic) compounds and their use in human and veterinary medicine
    申请人:Centre International de Recherches Dermatologiques Galderma (Cird
    公开号:US05387594A1
    公开(公告)日:1995-02-07
    Di(aromatic) compounds corresponding to the following formula: ##STR1## in which: Ar represents either ##STR2## n=1 or 2 or: ##STR3## X represents a divalent radical, Z represents O, S or a divalent radical, and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 represent a hydrogen atom or various organic radicals, and the salts of the compounds of formula (I) when R.sub.1 is a carboxylic acid function. Use in human and veterinary medicine and in cosmetics.
    对应以下公式的二芳基化合物:##STR1## 其中:Ar代表##STR2## n=1或2或:##STR3## X代表二价基团,Z代表O、S或二价基团,R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5代表氢原子或各种有机基团,以及当R.sub.1是羧酸功能时,公式(I)化合物的盐。用于人类和兽医学以及化妆品。
  • N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
    申请人:——
    公开号:US20030144329A1
    公开(公告)日:2003-07-31
    The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia: 1
    本发明涉及某些化合物的公式(I),这些化合物可用于治疗疾病,如癌症、代谢紊乱、2型糖尿病、血脂异常和/或高胆固醇血症。
  • Copper(II)-Catalyzed C–N Coupling of Aryl Halides and N-Nucleophiles Promoted by Quebrachitol or Diethylene Glycol
    作者:Fangyu Du、Qifan Zhou、Yang Fu、Yuanguang Chen、Ying Wu、Guoliang Chen
    DOI:10.1055/s-0039-1690707
    日期:2019.12
    Herein, we report the natural ligand quebrachitol (QCT) as a promoter for a Cu(II) catalyst, which is highly effective for N-arylation of various amines and related aryl halides. A series of diarylamine derivatives were obtained in high yields by using diethylene glycol (DEG) as both ligand and solvent. The C–N coupling reactions proceed under mild conditions and exhibit good functional group tolerance
    在本文中,我们报告了天然配体 quebrachitol (QCT) 作为 Cu(II) 催化剂的促进剂,它对各种胺和相关芳基卤化物的 N-芳基化非常有效。通过使用二甘醇(DEG)作为配体和溶剂,以高收率获得了一系列二芳胺衍生物。C-N偶联反应在温和的条件下进行并表现出良好的官能团耐受性。
  • Retinoidal Pyrimidinecarboxylic Acids. Unexpected Diaza-Substituent Effects in Retinobenzoic Acids.
    作者:Kiminori OHTA、Emiko KAWACHI、Noriko INOUE、Hiroshi FUKASAWA、Yuichi HASHIMOTO、Akiko ITAI、Hiroyuki KAGECHIKA
    DOI:10.1248/cpb.48.1504
    日期:——
    Several pyridine-and pyrimidine-carboxylic acids were synthesized as ligand candidates for retinoid nuclear receptors, retinoic acid receptors (RARs) and retinoic X receptors (RXRs). Although the pyridine derivatives, 6-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)carbamoyl]pyridine-3-carboxylic acid (2b) and 6-[(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)carboxamido]pyridine-3-carboxylic acid (5b) are more potent than the corresponding benzoic acid-type retinoids, Am80 (2a) and Am580 (5a), the replacement of the benzene ring of Am580 (5a), Am555 (6a), or Am55 (7a) with a pyrimidine ring caused loss of the retinoidal activity both in HL-60 cell differentiation assay and in RAR transactivation assay using COS-1 cells. On the other hand, pyrimidine analogs (PA series, 10 and 11) of potent RXR agonists (retinoid synergists) with a diphenylamine skeleton (DA series, 8 and 9) exhibited potent retinoid synergistic activity in HL-60 cell differentiation assay and activated RXRs. Among the synthesized compounds, 2-[N-n-propyl-N-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyl-2-naphthalenyl)amino]pyrimidene-5-carboxylic acid (PA013, 10e) is most active retinoid synergist in HL-60 assay.
    几种吡啶和嘧啶羧酸被合成为视黄酸核受体、视黄酸受体(RARs)和视黄酸X受体(RXRs)的配体候选物。虽然吡啶衍生物,6-[(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)氨基甲酰]吡啶-3-羧酸(2b)和6-[(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)羧酰胺]吡啶-3-羧酸(5b)比相应的苯甲酸型视黄酸更有效,如Am80(2a)和Am580(5a),但将Am580(5a)、Am555(6a)或Am55(7a)的苯环替换为嘧啶环会导致视黄酸活性在HL-60细胞分化试验和使用COS-1细胞的RAR转录激活试验中丧失。另一方面,具有二苯胺骨架(DA系列,8和9)的强效RXR激动剂(视黄酸协同剂)的嘧啶类似物(PA系列,10和11)在HL-60细胞分化试验中表现出强效的视黄酸协同活性并激活RXRs。在合成的化合物中,2-[N-正丙基-N-(5, 6, 7, 8-四氢-5, 5, 8, 8-四甲基-2-萘基)氨基]嘧啶-5-羧酸(PA013,10e)在HL-60试验中是最活跃的视黄酸协同剂。
  • RETINOID PRODRUG COMPOUND
    申请人:Muratake Hideaki
    公开号:US20100286427A1
    公开(公告)日:2010-11-11
    A compound represented by the following general formula (I): [R 1 to R 5 represent hydrogen atom, an alkyl group, or a trialkylsilyl group, X represents —NH—CO—, —CO—NH—, —N(COR 6 )—CO—, —CO—N(COR 7 )— (R 6 and R 7 represent a lower alkoxy group, or a carboxy-substituted phenyl group) etc.; and Z represents —Y—CH(R 12 )—COOH, —CHO, —CH═CH—COOH, or —COOR 13 (Y represents a single bond, —CH 2 —, —CH(OH)—, —CO—, —CO—NH—, or —CO—NH—CH 2 —CO—NH—, R 12 represents hydrogen atom or a lower alkyl group, and R 13 represents hydrogen atom, —CH(R 14 )—COOH(R 14 represents hydrogen atom, a lower alkyl group, or hydroxy group), —[CH 2 CH 2 —O] n —CH 2 —CH 2 —OH, —CH 2 —O—[CH 2 CH 2 —O] m —CH 2 —OH, or —[CH(CH 3 )—CO—O] p —CH(CH 3 )—COOH (m, n and p represent an integer of 1 to 100))], a salt thereof or an ester thereof, which has a property of being converted into a retinoid after absorption in vivo.
    由以下一般式(I)表示的化合物: [R1至R5代表氢原子、烷基或三烷基硅基,X代表—NH—CO—、—CO—NH—、—N(COR6)—CO—、—CO—N(COR7)—(R6和R7代表较低的烷氧基或羧基取代的苯基)等;Z代表—Y—CH(R12)—COOH、—CHO、—CH═CH—COOH或—COOR13(Y代表单键、—CH2—、—CH(OH)—、—CO—、—CO—NH—或—CO—NH—CH2—CO—NH—,R12代表氢原子或较低的烷基,R13代表氢原子、—CH(R14)—COOH(R14代表氢原子、较低的烷基或羟基),—[CH2CH2—O]n—CH2—CH2—OH、—CH2—O—[CH2CH2—O]m—CH2—OH或—[CH(CH3)—CO—O]p—CH(CH3)—COOH(m、n和p代表1至100的整数)],其盐或酯,具有在体内吸收后转化为视黄醇类物质的特性。
查看更多

同类化合物

(S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 顺式-4-(4-氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺盐酸盐 顺式-4-(3,4-二氯苯基)-1,2,3,4-四氢N-叔丁氧羰基-1-萘胺 顺式-1-苯甲酰氧基-2-二甲基氨基-1,2,3,4-四氢萘 顺式-1,2,3,4-四氢-5-环氧丙氧基-2,3-萘二醇 顺式-(1S,4S)-N-甲基-4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺扁桃酸盐 顺-5,6,7,8-四氢-6,7-二羟基-1-萘酚 顺-(+)-5-甲氧基-1-甲基-2-(二正丙基氨基)萘满马来酸 阿洛米酮 阿戈美拉汀杂质醇(A) 阿戈美拉汀杂质 钠2-羟基-7-甲氧基-1,2,3,4-四氢-2-萘磺酸酯 金钟醇 邻烯丙基苯基溴化镁 那高利特盐酸盐 那高利特 过氧化,1,1-二甲基乙基1,2,3,4-四氢-1-萘基 贝多拉君 螺<4.7>十二烷 蔡醇酮 萘磺酸,二癸基-1,2,3,4-四氢- 萘并[2,3-d]咪唑,2-乙基-5,6,7,8-四氢-(6CI) 萘亚胺 苯甲酸-(5,6,7,8-四氢-[2]萘基酯) 苯甲丁氮酮 苯甲丁氮酮 苯甲丁氮酮 苯并烯氟菌唑 舍曲林二甲基杂质盐酸盐 舍曲林EP杂质B 舍曲林 羟甲基四氢萘酚 美曲唑啉 罗替戈汀硫酸盐 罗替戈汀杂质18 罗替戈汀中间体 罗替戈汀中间体 罗替戈汀 罗替戈汀 纳多洛尔杂质 米贝地尔(二盐酸盐) 盐酸舍曲林 盐酸舍曲林 盐酸罗替戈汀 盐酸左布诺洛尔 盐酸四氢唑林 甲基缩合物 甲基6-[1-(3,5,5,8,8-五甲基-5,6,7,8-四氢-2-萘基)环丙基]烟酸酯 甲基-(2-吡咯烷-1-基甲基-1,2,3,4-四氢-萘-2-基)-胺 环丙烯并[a]茚,1-溴-1-氟-1,1a,6,6a-四氢-